Back to Erlotinib

Erlotinib

Showing 4 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	median follow-up [months]⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	4	62	18.0	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	EGFR targeting TKI	Erlotinib	—	Missing	intra-cranial	brain	—	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	2	Missing	G3 or higher: 2 pts	—	—
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	5	62	18.0	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	EGFR targeting TKI	Erlotinib	—	Missing	extra-cranial	lung	—	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	1	Missing	G3 or higher: 1 pt	—	—
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	1	62	18.0	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	EGFR targeting TKI	Erlotinib	—	Missing	extra-cranial	other	Abdomen	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Sperduto et al.	2013	Prospective	A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320	10.1016/j.ijrobp.2012.11.042	Missing	41	61	33.6	Lung cancer	metastatic	EGFR targeting TKI	Erlotinib	—	Missing	intra-cranial	brain	—	Missing	15.0	24.0	1	1	1	Missing	15.0	24.0	Treatment-rel.	—	—	20	unknown	any G3: 17 pts, any G4: 2 pts, any G5: 1pt	any G3: cytopenia, fatigue, dehydration, acne, anorexia, vasculitis, diarrhea, pneumonia, hyperkalemia, muscle weakness, confusion, ataxia, any G4: myocardial ischemia, brain necrosis, any G5: hemorrhagic stroke	—